Literature DB >> 27230862

Cognitive Behavioral Therapy for Patients with Social Anxiety Disorder Who Remain Symptomatic following Antidepressant Treatment: A Randomized, Assessor-Blinded, Controlled Trial.

Naoki Yoshinaga1, Satoshi Matsuki, Tomihisa Niitsu, Yasunori Sato, Mari Tanaka, Hanae Ibuki, Rieko Takanashi, Keiko Ohshiro, Fumiyo Ohshima, Kenichi Asano, Osamu Kobori, Kensuke Yoshimura, Yoshiyuki Hirano, Kyoko Sawaguchi, Masaya Koshizaka, Hideki Hanaoka, Akiko Nakagawa, Michiko Nakazato, Masaomi Iyo, Eiji Shimizu.   

Abstract

BACKGROUND: Although antidepressants are still a commonly used treatment for social anxiety disorder (SAD), a significant proportion of patients fail to remit following antidepressants. However, no standard approach has been established for managing such patients. This study aimed to examine the effectiveness of cognitive behavioral therapy (CBT) as an adjunct to usual care (UC) compared with UC alone in SAD patients who remain symptomatic following antidepressant treatment.
METHODS: This was a prospective randomized open-blinded end-point study with two parallel groups (CBT + UC, and UC alone, both for 16 weeks) conducted from June 2012 to March 2014. SAD patients who remain symptomatic following antidepressant treatment were recruited, and a total sample size of 42 was set based on pilot results.
RESULTS: Patients were randomly allocated to CBT + UC (n = 21) or UC alone (n = 21). After 16 weeks, adjusted mean reduction in the Liebowitz Social Anxiety Scale from baseline for CBT + UC and UC alone was -40.87 and 0.68, respectively; the between-group difference was -41.55 (-53.68 to -29.42, p < 0.0001). Response rates were 85.7 and 10.0% for CBT + UC and UC alone, respectively (p < 0.0001). The corresponding remission rates were 47.6 and 0.0%, respectively (p = 0.0005). Significant differences were also found in favor of CBT + UC for social anxiety symptoms, depressive symptoms, and functional impairment.
CONCLUSIONS: Our results suggest that in SAD patients who have been ineffectively treated with antidepressants, CBT is an effective treatment adjunct to UC over 16 weeks in reducing social anxiety and related symptoms.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27230862     DOI: 10.1159/000444221

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  14 in total

1.  Are young people with primary social anxiety disorder less likely to recover following generic CBT compared to young people with other primary anxiety disorders? A systematic review and meta-analysis.

Authors:  Rachel Evans; David M Clark; Eleanor Leigh
Journal:  Behav Cogn Psychother       Date:  2020-12-10

2.  Does cognitive behavioral therapy alter mental defeat and cognitive flexibility in patients with panic disorder?

Authors:  Shinobu Nagata; Yoichi Seki; Takayuki Shibuya; Mizue Yokoo; Tomokazu Murata; Yoichi Hiramatsu; Fuminori Yamada; Hanae Ibuki; Noriko Minamitani; Naoki Yoshinaga; Muga Kusunoki; Yasushi Inada; Nobuko Kawasoe; Soichiro Adachi; Keiko Oshiro; Daisuke Matsuzawa; Yoshiyuki Hirano; Kensuke Yoshimura; Michiko Nakazato; Masaomi Iyo; Akiko Nakagawa; Eiji Shimizu
Journal:  BMC Res Notes       Date:  2018-01-12

3.  Development and evaluation of a modified brief assertiveness training for nurses in the workplace: a single-group feasibility study.

Authors:  Yohei Nakamura; Naoki Yoshinaga; Hiroki Tanoue; Sayaka Kato; Sayoko Nakamura; Keiko Aoishi; Yuko Shiraishi
Journal:  BMC Nurs       Date:  2017-06-06

Review 4.  Treating social anxiety disorder remotely with cognitive therapy.

Authors:  Emma Warnock-Parkes; Jennifer Wild; Graham R Thew; Alice Kerr; Nick Grey; Richard Stott; Anke Ehlers; David M Clark
Journal:  Cogn Behav Therap       Date:  2020-07-16

5.  Internet-Based Cognitive Behavioral Therapy With Real-Time Therapist Support via Videoconference for Patients With Obsessive-Compulsive Disorder, Panic Disorder, and Social Anxiety Disorder: Pilot Single-Arm Trial.

Authors:  Kazuki Matsumoto; Chihiro Sutoh; Kenichi Asano; Yoichi Seki; Yuko Urao; Mizue Yokoo; Rieko Takanashi; Tokiko Yoshida; Mari Tanaka; Remi Noguchi; Shinobu Nagata; Keiko Oshiro; Noriko Numata; Motohisa Hirose; Kensuke Yoshimura; Kazue Nagai; Yasunori Sato; Taishiro Kishimoto; Akiko Nakagawa; Eiji Shimizu
Journal:  J Med Internet Res       Date:  2018-12-17       Impact factor: 5.428

6.  Effectiveness of Internet-Delivered Computerized Cognitive Behavioral Therapy for Patients With Insomnia Who Remain Symptomatic Following Pharmacotherapy: Randomized Controlled Exploratory Trial.

Authors:  Daisuke Sato; Naoki Yoshinaga; Eiichi Nagai; Kazue Nagai; Eiji Shimizu
Journal:  J Med Internet Res       Date:  2019-04-11       Impact factor: 5.428

7.  Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review.

Authors:  Wicher A Bokma; Guido A A M Wetzer; Jurriaan B Gehrels; Brenda W J H Penninx; Neeltje M Batelaan; Anton L J M van Balkom
Journal:  Depress Anxiety       Date:  2019-06-23       Impact factor: 6.505

8.  A feasibility study of the clinical effectiveness and cost-effectiveness of individual cognitive behavioral therapy for panic disorder in a Japanese clinical setting: an uncontrolled pilot study.

Authors:  Yoichi Seki; Shinobu Nagata; Takayuki Shibuya; Naoki Yoshinaga; Mizue Yokoo; Hanae Ibuki; Noriko Minamitani; Muga Kusunoki; Yasushi Inada; Nobuko Kawasoe; Soichiro Adachi; Kensuke Yoshimura; Michiko Nakazato; Masaomi Iyo; Akiko Nakagawa; Eiji Shimizu
Journal:  BMC Res Notes       Date:  2016-10-07

Review 9.  Treatment of anxiety disorders.

Authors:  Borwin Bandelow; Sophie Michaelis; Dirk Wedekind
Journal:  Dialogues Clin Neurosci       Date:  2017-06       Impact factor: 5.986

10.  Randomised controlled trial on the effect of internet-delivered computerised cognitive-behavioural therapy on patients with insomnia who remain symptomatic following hypnotics: a study protocol.

Authors:  Daisuke Sato; Naoki Yoshinaga; Eiichi Nagai; Hideki Hanaoka; Yasunori Sato; Eiji Shimizu
Journal:  BMJ Open       Date:  2018-01-30       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.